{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:02:17Z","timestamp":1794301337801,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40256-022-00563-4","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T16:03:57Z","timestamp":1676304237000},"page":"197-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct01994889","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rahul","family":"Bhambri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Carmine","family":"Colavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kemner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrin","family":"Benjumea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gilstrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"563_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021;3:488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006.","journal-title":"JACC CardioOncol."},{"key":"563_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"key":"563_CR3","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","volume":"8","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Judge DP, Hoffman JE, Gundapaneni B, Keohane D, Sultan MB, et al. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021;8:3875\u201384. https:\/\/doi.org\/10.1002\/ehf2.13541.","journal-title":"ESC Heart Fail."},{"key":"563_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2217\/cer-2021-0071","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Young R, van Doornewaard A, et al. Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. J Comp Eff Res. 2021;10:927\u201338. https:\/\/doi.org\/10.2217\/cer-2021-0071.","journal-title":"J Comp Eff Res."},{"key":"563_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222-8.e1. https:\/\/doi.org\/10.1016\/j.ahj.2012.04.015.","journal-title":"Am Heart J"},{"key":"563_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033.","journal-title":"J Am Coll Cardiol"},{"key":"563_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7:709\u201316. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010.","journal-title":"JACC Heart Fail."},{"key":"563_CR8","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006075.","journal-title":"Circ Heart Fail"},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10:141\u201359. https:\/\/doi.org\/10.1007\/s40119-021-00219-5.","journal-title":"Cardiol Ther."},{"key":"563_CR10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338.","journal-title":"Eur Heart J"},{"key":"563_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","volume":"21","author":"M Gertz","year":"2020","unstructured":"Gertz M, Adams D, Ando Y, Beir\u00e3o JM, Bokhari S, Coelho T, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21:198. https:\/\/doi.org\/10.1186\/s12875-020-01252-4.","journal-title":"BMC Fam Pract"},{"key":"563_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","volume":"32","author":"Y Bennani Smires","year":"2016","unstructured":"Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, M\u00e9jean S, et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging. 2016;32:1403\u201313. https:\/\/doi.org\/10.1007\/s10554-016-0915-z.","journal-title":"Int J Cardiovasc Imaging"},{"key":"563_CR13","unstructured":"Pfizer. Prescribing information for VYNDAQEL (tafamidis meglumine capsule, liquid filled) and VYNDAMAX (tafamidis capsule, liquid filled). 2019. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11685. Accessed 31 Mar 2022."},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"key":"563_CR15","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e876\u201394. https:\/\/doi.org\/10.1161\/CIR.0000000000001062.","journal-title":"Circulation"},{"key":"563_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","volume":"9","author":"AS Hafeez","year":"2020","unstructured":"Hafeez AS, Bavry AA. Diagnosis of transthyretin amyloid cardiomyopathy. Cardiol Ther. 2020;9:85\u201395. https:\/\/doi.org\/10.1007\/s40119-020-00169-4.","journal-title":"Cardiol Ther."},{"key":"563_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2013evidence base and standardized methods of imaging. J Cardiac Fail. 2019;25:e1-39. https:\/\/doi.org\/10.1016\/j.cardfail.2019.08.001.","journal-title":"J Cardiac Fail"},{"key":"563_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","volume":"27","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2\u2013diagnostic criteria and appropriate utilization. J Nuclear Cardiol. 2020;27:659\u201373. https:\/\/doi.org\/10.1007\/s12350-019-01761-5.","journal-title":"J Nuclear Cardiol."},{"key":"563_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10741-019-09776-3","volume":"24","author":"AG Rigopoulos","year":"2019","unstructured":"Rigopoulos AG, Ali M, Abate E, Torky AR, Matiakis M, Mammadov M, et al. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail Rev. 2019;24:521\u201333. https:\/\/doi.org\/10.1007\/s10741-019-09776-3.","journal-title":"Heart Fail Rev"},{"key":"563_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","volume":"1","author":"KJ Rothman","year":"1990","unstructured":"Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43\u20136.","journal-title":"Epidemiology"},{"key":"563_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail. 2021;9:115\u201323. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.011.","journal-title":"JACC Heart Fail."},{"key":"563_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:113\u201322. https:\/\/doi.org\/10.1016\/j.jchf.2013.11.004.","journal-title":"JACC Heart Fail."},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232\u20139. https:\/\/doi.org\/10.1080\/07853890701842988.","journal-title":"Ann Med"},{"key":"563_CR24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141:1214\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045093.","journal-title":"Circulation"},{"key":"563_CR25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaccao.2021.06.002","volume":"3","author":"AT Nguyen","year":"2021","unstructured":"Nguyen AT, Alexander KM. Mistaken identity: using bone scintigraphy to diagnose cardiac amyloidosis in patients with a monoclonal gammopathy. JACC CardioOncol. 2021;3:594\u20137. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.002.","journal-title":"JACC CardioOncol."},{"key":"563_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2021.11.048","volume":"167","author":"JM Bourque","year":"2022","unstructured":"Bourque JM, Schepart A, Bhambri R, Casta\u00f1o A, O\u2019Brien A, Chen Y, et al. Temporal trends in diagnostic testing patterns for wild-type transthyretin amyloid cardiomyopathy in the Medicare fee-for-service population. Am J Cardiol. 2022;167:98\u2013103. https:\/\/doi.org\/10.1016\/j.amjcard.2021.11.048.","journal-title":"Am J Cardiol"},{"key":"563_CR27","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cardfail.2019.07.151","volume":"25","author":"A Huda","year":"2019","unstructured":"Huda A, Shah SJ, Castano A, Niyogi A, Schumacher J, Stewart M, et al. A machine learning model for the systematic identification of wild-type transthyretin cardiomyopathy. J Cardiac Fail. 2019;25:S53\u20134. https:\/\/doi.org\/10.1016\/j.cardfail.2019.07.151.","journal-title":"J Cardiac Fail"},{"key":"563_CR28","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1038\/s41467-021-22876-9","volume":"12","author":"A Huda","year":"2021","unstructured":"Huda A, Casta\u00f1o A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. 2021;12:2725. https:\/\/doi.org\/10.1038\/s41467-021-22876-9.","journal-title":"Nat Commun"},{"key":"563_CR29","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.cjca.2021.07.134","volume":"37","author":"C Willis","year":"2021","unstructured":"Willis C, Kawamoto K, Watanabe A, Biskupiak J, Nolen K, Blackner L, et al. Screening of patients at risk for wild-type ATTR-CM using a computational machine learning algorithm. Can J Cardiol. 2021;37:S65. https:\/\/doi.org\/10.1016\/j.cjca.2021.07.134.","journal-title":"Can J Cardiol"},{"key":"563_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12911-018-0625-7","volume":"18","author":"R Zhang","year":"2018","unstructured":"Zhang R, Ma S, Shanahan L, Munroe J, Horn S, Speedie S. Discovering and identifying New York heart association classification from electronic health records. BMC Med Inform Decis Mak. 2018;18:48. https:\/\/doi.org\/10.1186\/s12911-018-0625-7.","journal-title":"BMC Med Inform Decis Mak"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00563-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T15:36:55Z","timestamp":1678462615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00563-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00563-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"14 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Pfizer contributed to the study design and management and collection of data. In their role as authors, employees of Pfizer were involved in the interpretation of data; preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication, along with their co-authors. The study sponsor approved the manuscript from an intellectual property perspective but had no right to veto the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Funding Source"}},{"value":"Rahul Bhambri, A. Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, and Jason Kemner are employees of Pfizer and own stock\/stock options. Aaron Crowley and Darrin Benjumea are employees of Genesis Research, LLC, which was contracted and paid by Pfizer for participation in this study. Lauren Gilstrap has no relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was conducted in accordance with the Code of Ethics of the World Medical Association (the Declaration of Helsinki).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This study was based on de-identified data from Optum\u2019s longitudinal EHR. No additional consent was required to conduct or publish this analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/Consent for publication"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See  for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Comorbidity diagnostic codes are provided in the Supplementary Material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RB, ACC, MB, YC, JA, AR, JK, AC, and DB contributed to the study conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, and writing \u2013 review and editing. RB, ACC, MB, YC, JA, AR, and JK additionally contributed to the funding acquisition and resourcing. LG contributed to the formal analysis, investigation, validation, visualization, and writing \u2013 review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}